Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Applied Health Economics and Health Policy
Published in: Applied Health Economics and Health Policy 1/2017

01-02-2017 | Editorial

‘Appropriateness’ in Italy: A ‘Magic Word’ in Pharmaceuticals?

Authors: Livio Garattini, Anna Padula

Published in: Applied Health Economics and Health Policy | Issue 1/2017

Login to get access

Excerpt

Appropriateness is the term largely used in Italy in the debate on efficient allocation of health-care services. Various domestic laws mention it, stressing its importance for enhancing the performance of the Italian National Health Service (INHS). The latest finance law even introduced a ‘Commission for the Promotion of Appropriateness in the INHS’, aiming at ‘leading a continuous evaluation of existing and forthcoming health care services and assessing their economic impact’ [1]. …
Footnotes
1
We used the MeSH terms ‘inappropriate prescribing’ for the search. From the 359 studies published in English on the subject up to December 2015, 353 were discarded, being: (1) reviews focused on specific medicines (182) or prescriptions in older patients and/or polypharmacy (84); (2) studies on methods, evaluation criteria and guidelines (16) or other topics (71).
 
Literature
1.
2.
3.
4.
Garattini L, Casadei G. Risk sharing agreements: what lessons from Italy? Int J Technol Assess Care. 2011;27(2):169–72.CrossRef
5.
6.
Santos AP, Silva DT, Alves-Conceição V, Antoniolli AR, Lyra DP Jr. Conceptualizing and measuring potentially inappropriate drug therapy. J Clin Pharm Ther. 2015;40(2):167–76.CrossRefPubMed
7.
Kaufmann CP, Tremp R, Hersberger KE, Lampert ML. Inappropriate prescribing: a systematic overview of published assessment tools. Eur J Clin Pharmacol. 2014;70(1):1–11.CrossRefPubMed
8.
O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing: criteria, detection and prevention. Drugs Aging. 2012;29(6):437–52.CrossRefPubMed
9.
Dimitrow MS, Airaksinen MS, Kivelä SL, Lyles A, Leikola SN. Comparison of prescribing criteria to evaluate the appropriateness of drug treatment in individuals aged 65 and older: a systematic review. J Am Geriatr Soc. 2011;59(8):1521–30.CrossRefPubMed
10.
Gallagher P, Barry P, O’Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007;32(2):113–21.CrossRefPubMed
11.
Lexchin J. Improving the appropriateness of physician prescribing. Int J Health Serv. 1998;28(2):253–67.CrossRefPubMed
12.
World Health Organization. Appropriateness in health care services—report on a World Health Organization workshop. Koblenz: World Health Organization; 2000.
13.
Fick DM, Semla TP, Beizer J, Brandt N, Dombrowski R, DuBeau CE, Eisenberg W, Epplin JJ, Flanagan N, Giovannetti E, Hanlon J, Hollmann P, Laird R, Linnebur S, Sandhu S, Steinman M. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.CrossRef
14.
O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8.CrossRefPubMed
15.
Garattini L, Casadei G. Health Technology Assessment: for whom the bell tolls? Eur J Health Econ. 2008;9(4):311–2.CrossRefPubMed
16.
Garattini L, van de Vooren K, Curto A. Regional HTA in Italy: promising or confusing? Health Policy. 2012;108(2–3):203–6.CrossRefPubMed
17.
Garattini L, Curto A, Freemantle N. Access to primary care in Italy: time for a shake-up? Eur J Health Econ. 2016;17(2):113–6.CrossRefPubMed
18.
Garattini L, Curto A, van de Vooren K. Italian risk-sharing agreements on drugs: are they worthwhile? Eur J Health Econ. 2015;16(1):1–6.CrossRefPubMed
19.
Ministero della Salute. Direzione Generale della Digitalizzazione del Sistema Informativo Sanitario e della Statistica. Personale delle A.S.L. e degli Istituti di ricovero pubblici ed equiparati. Anno 2012.
Metadata
Title
‘Appropriateness’ in Italy: A ‘Magic Word’ in Pharmaceuticals?
Authors
Livio Garattini
Anna Padula
Publication date
01-02-2017
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 1/2017
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-016-0240-7

Other articles of this Issue 1/2017

Applied Health Economics and Health Policy 1/2017 Go to the issue

Original Research Article

Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease

Current Opinion

The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements

Short Communication

Promoting Antibacterial Drug Development: Select Policies and Challenges

Original Research Article

Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications

Original Research Article

A Cost-Utility Analysis of Prostate Cancer Screening in Australia

Original Research Article

Economic Evaluation in Ethiopian Healthcare Sector Decision Making: Perception, Practice and Barriers